Mitochondrial DNA Levels in Fat and Blood Cells from Patients with Lipodystrophy or Peripheral Neuropathy and the Effect of 90 Days of High-Dose Coenzyme Q Treatment: A Randomized, Double-Blind, Placebo-Controlled Pilot Study | Zendy

Eric R. Christensen | Zendy; Marc Stegger | Zendy; Søren JensenFangel | Zendy; Alex Lund Laursen | Zendy; Lars Østergaard | Zendy

Open Access

Mitochondrial DNA Levels in Fat and Blood Cells from Patients with Lipodystrophy or Peripheral Neuropathy and the Effect of 90 Days of High-Dose Coenzyme Q Treatment: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Author(s) -

Eric R. Christensen,

Marc Stegger,

Søren JensenFangel,

Alex Lund Laursen,

Lars Østergaard

Publication year - 2004

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/424881

Subject(s) - lipodystrophy , medicine , double blind , peripheral neuropathy , placebo , randomized controlled trial , endocrinology , gastroenterology , peripheral blood , pathology , immunology , diabetes mellitus , alternative medicine , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy

Mitochondrial toxicity can be induced by reverse-transcriptase inhibitors, and an association between levels of mitochondrial DNA (mtDNA) per cell and lipodystrophy, peripheral neuropathy, and HIV infection per se has been suggested. Studies aimed at increasing the oxidative capacity in HIV-infected patients have been sparse.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research